TLDR
- Q32 Bio stock jumped ~60% after reporting positive 36-week data from its Phase 2a SIGNAL-AA trial for bempikibart in alopecia areata
- The trial hit its primary endpoint with a 35.3% mean reduction in SALT score in the mITT population
- 40% of patients achieved SALT-20 response at Week 36; one patient showed complete hair regrowth
- Bempikibart showed a clean safety profile — no serious or Grade 3+ treatment-related adverse events
- Q32 Bio plans to launch a registration-directed program in the first half of 2027
Q32 Bio (QTTB) stock jumped roughly 60% on Monday after the company released positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a clinical trial. The data tested bempikibart in patients with severe or very severe alopecia areata.
The stock was trading up over 63% on the session, pushing the company’s market cap to around $265.5 million.
The trial enrolled 33 patients with baseline SALT scores between 50 and 100. That’s a patient population with limited treatment options and, for many, prior treatment failures.
The primary endpoint was met. The trial showed a mean 35.3% reduction in SALT score from baseline in the prespecified modified intent-to-treat (mITT) analysis.
On responder rates, 40% of patients hit SALT-20 at Week 36 in the mITT analysis. A further 44% reached SALT-30 and SALT-50. One patient achieved complete hair regrowth.
Worth noting: 36.4% of the enrolled patients had previously been treated with oral JAK inhibitors — the current standard of care. That makes the response data more meaningful.
Patients received 200mg of bempikibart weekly for four doses as a loading regimen, then 200mg every other week for the remaining 32 weeks.
Safety Profile Holds Up
On safety, bempikibart came through without any serious adverse events or Grade 3+ treatment-related events. The most common side effect was injection site reactions at 36.3%, which were mostly mild and cleared on their own.
The company also completed a Part A open-label extension, which showed long-term safety and durable or improved hair growth, supporting the case for a maintenance dosing approach.
Bempikibart is a fully human anti-IL-7Rα antibody that works by blocking IL-7 and TSLP signaling to re-regulate adaptive immune function.
Balance Sheet Tidied Up
On the business side, Q32 Bio paid off and terminated its roughly $6.8 million loan with Silicon Valley Bank on June 24, 2026. That removes a lender from the picture as the company moves toward late-stage development.
Q32 Bio said it intends to advance a registration-directed program for bempikibart in alopecia areata in the first half of 2027. Full results from Part B will be presented at a future medical meeting.
The most recent analyst rating on QTTB is a Hold with a $10.00 price target.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
